Kane Biotech Stock Performance
| KNBIF Stock | USD 0.08 0.0003 0.39% |
The company secures a Beta (Market Risk) of 0.0999, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kane Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kane Biotech is expected to be smaller as well. At this point, Kane Biotech has a negative expected return of -0.51%. Please make sure to verify Kane Biotech's treynor ratio and the relationship between the daily balance of power and relative strength index , to decide if Kane Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kane Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's forward indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 1 M | |
| Total Cashflows From Investing Activities | -373.5 K |
Kane |
Kane Biotech Relative Risk vs. Return Landscape
If you would invest 11.00 in Kane Biotech on August 29, 2024 and sell it today you would lose (3.33) from holding Kane Biotech or give up 30.27% of portfolio value over 90 days. Kane Biotech is currently producing negative expected returns and takes up 3.2625% volatility of returns over 90 trading days. Put another way, 29% of traded otc stocks are less volatile than Kane, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Kane Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kane Biotech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Kane Biotech, and traders can use it to determine the average amount a Kane Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.157
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KNBIF |
Estimated Market Risk
| 3.26 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.51 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kane Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kane Biotech by adding Kane Biotech to a well-diversified portfolio.
Kane Biotech Fundamentals Growth
Kane OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Kane Biotech, and Kane Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kane OTC Stock performance.
| Return On Equity | -5.97 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.80) % | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 124.83 M | |||
| Price To Earning | 4.68 X | |||
| Price To Book | 102.61 X | |||
| Price To Sales | 3.45 X | |||
| Revenue | 1.61 M | |||
| EBITDA | (4.25 M) | |||
| Cash And Equivalents | 2.53 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 7.12 % | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (2.29 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 6.13 M | |||
About Kane Biotech Performance
By analyzing Kane Biotech's fundamental ratios, stakeholders can gain valuable insights into Kane Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kane Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kane Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States.Things to note about Kane Biotech performance evaluation
Checking the ongoing alerts about Kane Biotech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Kane Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kane Biotech generated a negative expected return over the last 90 days | |
| Kane Biotech has some characteristics of a very speculative penny stock | |
| Kane Biotech has high historical volatility and very poor performance | |
| Kane Biotech has accumulated 1.12 M in total debt with debt to equity ratio (D/E) of 7.12, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kane Biotech has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kane Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Kane Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kane Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kane to invest in growth at high rates of return. When we think about Kane Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.61 M. Net Loss for the year was (4.6 M) with profit before overhead, payroll, taxes, and interest of 568.44 K. | |
| Kane Biotech has accumulated about 2.53 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 27.0% of Kane Biotech outstanding shares are owned by corporate insiders |
- Analyzing Kane Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kane Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Kane Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kane Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kane Biotech's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Kane Biotech's otc stock. These opinions can provide insight into Kane Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kane OTC Stock analysis
When running Kane Biotech's price analysis, check to measure Kane Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kane Biotech is operating at the current time. Most of Kane Biotech's value examination focuses on studying past and present price action to predict the probability of Kane Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kane Biotech's price. Additionally, you may evaluate how the addition of Kane Biotech to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |